A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease
| Autor: | Gareth Maher-Edwards, Andrew Lockhart, Jeni De'Ath, Arseniy Lavrov, Carly Barnett |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Rilapladib medicine.medical_specialty Pathology Albumin quotient Amyloid beta medicine.drug_class Lp-PLA2 Placebo Cerebrospinal fluid Cognition Internal medicine medicine Dementia Cerebrovascular disease Neurofilament light chain biology Memantine Featured Article Alzheimer's disease medicine.disease Small vessel disease Clinical trial Psychiatry and Mental health Tolerability Acetylcholinesterase inhibitor SB659032 biology.protein Neurology (clinical) Tau Psychology Amyloid-beta peptide Biomarkers medicine.drug |
| Zdroj: | Alzheimer's & Dementia : Translational Research & Clinical Interventions |
| ISSN: | 2352-8737 |
| DOI: | 10.1016/j.trci.2015.06.003 |
| Popis: | Background The lipoprotein-associated phospholipase A 2 inhibitor (Lp-PLA 2 ), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer's disease (AD). Methods One hundred twenty-four subjects with possible mild AD and with neuroimaging evidence of cerebrovascular disease were randomized to placebo or 250-mg rilapladib once daily, for 24 weeks, in addition to stable background acetylcholinesterase inhibitor and/or memantine. The study assessed the safety and tolerability of rilapladib and its effects on cognition, mechanistic, and disease-related biomarkers. Although the overall intent behind the study was to take a broad exploratory view of the data, two primary end points of interest (cerebrospinal fluid [CSF] amyloid beta peptide 1–42 [Aβ 1–42 ] and CogState executive function/working memory [EF/WM] composite score at week 24) were prespecified in the analysis plan for inferential statistical analysis. Results Rilapladib was well tolerated with no significant safety concerns. A significant difference from placebo was observed for rilapladib on change from baseline in EF/WM (effect size, 0.45; P = .026). There was no significant difference between groups on the change from baseline in CSF Aβ 1–42 ( P = .133). Preliminary evidence of effects was detected on other mechanistic (albumin quotient) and disease-related biomarkers (tau/P-tau and neurofilament light chain). Conclusion These data provide initial evidence supporting Lp-PLA 2 inhibition as a novel treatment for dementia. Clinical Trial Registration Clinicaltrials.gov identifier: NCT01428453. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text